DCI Research

In a global phase 1/2 clinical trial, sotorasib “demonstrated meaningful anticancer activity in patients with heavily pre-treated KRAS G12C–mutated advanced pancreatic cancer.”

The hybrid retreat showcased the latest gastric cancer, blood cancer, pediatric sarcoma, glioblastoma, breast cancer, and immune micro-environment research.

DCI leaders Leah Zullig, PhD, MPH, and Kevin Oeffinger, MD, developed ONE TEAM, a tool that encourages patients to manage their own health.

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.

Peter Fecci, MD, PhD, is the co-editor of the new e-book — "It Takes a Village: The Expanding Multi-Disciplinary Approach to Brain Metastasis."

DCI member H. Kim Lyerly, MD, and pediatric neuro-oncologist Daniel Landi, MD, are co-leaders on the new cross-institutional project.

The Duke Med Alumni News Fall '22 Issue's cover story is "Researchers at Duke are Creating More Precise Approaches to Stopping Tumors."

As Duke celebrates more than 50 years of cancer breakthroughs, a new research program works toward a future when no one ever develops cancer.

Can a new test diagnose pancreatic cancer in the early stages?

The 2022 Web of Science citation index of Most Cited Scientists — nearly 7,000 authors worldwide — includes 30 researchers at Duke.

Here are some of the DCI faculty, researchers, and clinical providers whose work has recently been featured in the media, trades, journals, at Duke and the DCI blog.

The Duke BioRepository & Precision Pathology Center, a Duke School of Medicine Service Center and DCI Shared Resource turns 10.

Learn how the Precision Cancer Medicine Initiative is advancing research, extending lives, and breaking down barriers to access.

Learn about some notable BRPC/DCI cancer research collaborations and why the partnership is core to winning big grants for cancer research.

Learn about new developments in next generation molecular sequencing tests at the DUHS Clinical Labs' Clinical Molecular Diagnostics Laboratory.

A family history of cancer and genetic variants that might be inherited appear to be important risk factors for Black men diagnosed with early-onset prostate cancer.

DCI researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire.

Researchers mapping a molecular atlas for ductal carcinoma in situ have developed a predictive model to distinguish which cases will progress.

STUDY: Non-Hispanic Black patients are less likely to receive guideline-appropriate treatment for ovarian cancer than non-Hispanic White patients.

Tomi Akinyemiju, PhD, DCI epidemiologist and associate director, COEE, has received Duke funds to research climate change, radon exposure & lung cancer.

Two promising metastatic breast cancer drug discoveries emerge from the McDonnell Lab into the clinic.

DCI oncologists — doctors Davidson, Kamal, Moss, Secord, Menendez, and Kelley — blaze a trail, at the national level, in breast & gynecologic cancers.

Amanda Randles, PhD, will use the Pioneer Award to create AI models that estimate a person’s blood flow dynamics over time with the help of wearable devices like smart watches.

A team led by Duke biochemistry professor Bruce Donald, PhD, has developed an algorithm to predict how mutations in an enzyme will affect a drug’s efficacy.

The Radiation Research Society bestowed its highest honor — the Failla Memorial Lecture Award — on Michael B. Kastan, MD, PhD, executive director of DCI.

Congratulations to David Kirsch, MD, PhD, whose NCI Outstanding Investigator Award to study radiation and sarcoma biology has been renewed for another 7 years.

DCI radiation oncologist Christine Eyler, MD, PhD, was awarded an NCI Mentored Clinical Scientist Research Career Development Award for rectal cancer and chemo-radiotherapy research.

Brent Hanks, MD, PhD, and his lab team will trial a drug that targets the NLRP3 pathway, so as to unblock immunotherapy from working in melanoma patients.

Zach Reitman, MD, PhD, was awarded an NCI Mentored Clinical Scientist Research CDA for research into targeted radiation therapy in pediatric brainstem tumors.

Five questions for gynecologic oncologist Brittany Davidson, MD, about the best approach to patient goals and treatment expectations in terminal ovarian cancer

New nanoparticle shape can greatly enhance signals from multiple separate biomarkers at once, accurately detecting head and neck cancers without biopsies to improve global health

The Division of Gynecologic Oncology, Duke Department of OB-GYN commemorates 50 years of innovation and care.

"Just ASK," a course developed and piloted at DCI by Nadine Barrett, PhD, to help improve equity, diversity, and inclusion in cancer clinical trials, has gone national.

A research team led by Ann Marie Pendergast, PhD, found, in animal studies, that a leukemia drug disrupted HER2-positive breast cancer-spread to the brain.

Trudy G. Oliver, PhD, has joined DCI from the Huntsman Cancer Institute as a Duke Science and Technology Scholar. Her research focuses on subtypes of lung cancer.

David Darr has been named Associate Director of Administration and Senior Director for Research Strategy and Operations for DCI, effective August 15.

Association was evident for patients of different ethnicities, those with government and private insurance, and those treated at different types of health care facilities.

DCI GI oncologist John Strickler, MD, to present positive topline results of a pivotal phase 2 homegrown clinical trial in HER2+ metastatic colorectal cancer.

John Wayne Cancer Foundation is funding research by breast surgical oncologist Maggie DiNome, MD, to create a molecular-based way to predict cancer spread to lymph nodes.
 

Kristen Batich, MD, PhD, a Duke Neurosurgery postdoctoral fellow in the Sampson Lab, will research anti-tumor immunity in brain tumors.

DCI cardio-oncologist Susan Dent, MD, is lead investigator for DCI-enrolled patients in this NIH-funded multi-site breast cancer study.

Black, Hispanic, Asian-American people and other groups have a higher risk for stomach cancer. Early detection & treatment of a common stomach bacterium can prevent it.

A study co-led by DCI researcher Harry P. Erba, MD, PhD, demonstrated that quizartinib plus chemo doubled AML survival time.

A DCI study led by Shelley Hwang, MD, MPH, shows the potential of new imaging technology to help avoid repeat surgery after lumpectomy.

Achieving health through advocacy, Duke Consortium for Inflammatory Breast Cancer expands its community outreach with Duke students taking the lead.

Christopher Counter, PhD, associate director of Basic Research, is a member of a group receiving an international Cancer Grand Challenges Grant to investigate origins of cancer.

Enabling or inhibiting a certain enzyme could trigger the body’s natural immune response according to a study in Nature by Duke immunologist Edward Miao, MD, PhD, and colleagues.

DCI study led by Gayathri Devi, PhD, finds chronic stresses such as racism and poverty alter cellular functions that promote tumor growth and proliferation

DCI cancer disparities and healthcare delivery researchers Steven Patierno, PhD, and Nadine Barrett, PhD, are part of national efforts to mitigate cancer health disparities.